Health ❯ Healthcare ❯ Medical Research ❯ Clinical Trials

Cancer Treatment

Implanted Cesium-131 Tiles Cut Recurrences and Boost Survival in ROADS Phase III Trial

Intraoperative cesium-131 tiles deliver immediate targeted radiation, reducing cavity recurrences, shortening time to finish cranial care.

Imfinzi With Enfortumab Vedotin Improves Survival in Phase III Bladder Cancer Trial

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Single CAR T Infusion Clears Residual Disease in High-Risk Smoldering Myeloma Trial

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

Morning Immunotherapy Boosts Survival in Lung Cancer Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial